Weekly entry and exit
The Aescap Genetics Fund was established in early 2022. It is an open-ended fund that allows you to buy and sell units on a weekly basis. It invests in listed biotech companies that develop and bring to market new genetic medical treatments, such as gene, RNA and cell therapies. The advantage of genetic medicines is that they tackle the cause of diseases rather than just the symptoms.
The Aescap Genetics Fund invests in a concentrated portfolio of around 20 listed biotech and life sciences companies.
* From the fund’s launch in 2022 until 1 January 2026. ** Lower fees apply to amounts over 10 million
The Aescap Genetics Fund is actively managed on a ‘high conviction’ basis, drawing on extensive fundamental analysis combined with close engagement with management and relevant experts.
Selection based on future earning power, strong management and limited risk. Preference is given to companies with medicines already on the market and a broad pipeline of distinctive drug candidates.
Preference is given to companies with a technology platform capable of addressing multiple therapeutic areas and which out-licences parts of it to generate additional revenue through milestone payments and royalties.
Discipline in stock selection, constant monitoring, and buying and selling. The volatility of biotech shares creates buy-low/sell-high opportunities for an experienced fund manager.
A balanced portfolio, diversified across disease areas, technologies, geographies and development stages. A maximum of 25% of AUM in high-risk / high-return positions. Rebalancing based on target price versus current market price.
We calculate, we don’t speculate. Every company is valued using a discounted cash flow analysis, informed by proprietary field research.
During a meeting, you will find out everything there is to know about the fund’s strategy.
Send an email to our team →Highly experienced in evaluating clinical trial data and translating it into revenue potential.
A dedicated team of AI engineers that provides data-driven insights to support investment decisions.
Continuous interaction with the management of portfolio companies: a private equity mindset in a public market.
The investment team has invested more than €10 million in the fund.
The low correlation and high volatility of biotech shares create ideal opportunities to buy low and sell high.
Access to doctors, health insurers, patients and experienced portfolio advisors for in-depth medical and scientific expertise.
To minimise investment risks, the fund spreads its portfolio across diverse diseases, various stages of company development and different geographical areas. The fund identifies a number of risks for investors:
For an overview of identified risks, please refer to the prospectus available for download on this page.
The fund manager, Privium Fund Management BV, is regulated by the AFM and DNB and works exclusively with independent, specialist firms for custody and administration.
Aescap Genetics (the Fund) aims to create value by investing in publicly traded shares of genetics biotechnology and life sciences companies. The Fund invests in highly innovative companies that develop and market new genetic medical treatments such as gene, RNA and cell therapies. The Fund can, to a limited extent, also invest in companies that develop and market medical genetic diagnostics. The Fund’s objective is to achieve an average minimum annual net return (after deduction of costs) of >20 percent over 4-5 years. The Fund will typically invest in companies with the potential to (more than) double their share price over the same period.
Next to the objective of creating a financial return for investors, the Fund also promotes a social characteristic and is therefore classified under article 8 of the Sustainable Finance Disclosure Regulation (SFDR). The main focus of the Fund’s investments is in researching, developing, or producing treatment/solutions for diseases with a high unmet medical need. A high unmet medical need has been defined as diseases that are characterized by an (inadequacy of) available treatments, which severely impact the patient and the healthcare system, prevalent in the geographies the company currently markets or plans to market or distribute its current or future product(s).
The Fund aims to construct a portfolio of approximately eighteen companies that contribute to the social characteristic, and of which a minimum proportion of 30 percent (of the invested capital of the Fund) are considered sustainable investment. Invested capital consists of the Fund’s assets, excluding cash.
Next to establishing which sustainability risks are considered material for each investee company based on the Sustainability Accounting Standards Board (SASB), the Fund also analyses the investee companies’ preparedness to these sustainability risks as part of its due diligence process. The Fund takes the Principal Adverse Impact (PAI) indicators into account to determine if an investment can be considered sustainable. It investigates the processes and policies of any potential investment on environmental and social risks in the biotechnology sector as defined by the SASB and by the PAI indicators.
Monitoring of investee companies regarding their Environmental, Social and Governance (ESG) performance takes place monthly based on sustainability risks, investment allocation towards the social characteristic and the proportion of the investments determined as sustainable.
The Fund engages with investee companies to improve their ESG performance. Engagement can consist of meetings with management, data requests to investor relations to improve the policies and practices, or formal shareholder voting when considered necessary.
The Fund reports on a monthly and quarterly basis with updates on the financial returns. The Fund publishes an annual PAI report highlighting the engagement activities as well as any changes in policies and practices of the investee companies.
Download the relevant fund documents for the Aescap Genetics fund. Please contact us if you require further information.
Get in touch for a personal conversation or subscribe to our newsletter.
